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in BALB/c Mice
Regino Mercado-Lubo,1 Mary P. Leatham,1 Tyrrell Conway,2 and Paul S. Cohen1*
Department of Cell and Molecular Biology, University of Rhode Island, Kingston, Rhode Island 028811,1 and Department of
Botany and Microbiology, University of Oklahoma, Norman, Oklahoma 7301922
Received 31 October 2008/Returned for modification 9 December 2008/Accepted 11 January 2009
Previously, we showed that the Salmonella enterica serovar Typhimurium SR-11 tricarboxylic acid (TCA)
cycle must operate as a complete cycle for full virulence after oral infection of BALB/c mice (M. Tchawa Yimga,
M. P. Leatham, J. H. Allen, D. C. Laux, T. Conway, and P. S. Cohen, Infect. Immun. 74:1130–1140, 2006). In
the same study, we showed that for full virulence, malate must be converted to both oxaloacetate and pyruvate.
Moreover, it was recently demonstrated that blocking conversion of succinyl-coenzyme A to succinate atten-
uates serovar Typhimurium SR-11 but does not make it avirulent; however, blocking conversion of succinate
to fumarate renders it completely avirulent and protective against subsequent oral infection with the virulent
serovar Typhimurium SR-11 wild-type strain (R. Mercado-Lubo, E. J. Gauger, M. P. Leatham, T. Conway, and
P. S. Cohen, Infect. Immun. 76:1128–1134, 2008). Furthermore, the ability to convert succinate to fumarate
appeared to be required only after serovar Typhimurium SR-11 became systemic. In the present study, evidence
is presented that serovar Typhimurium SR-11 mutants that cannot convert fumarate to malate or that cannot
convert malate to both oxaloacetate and pyruvate are also avirulent and protective in BALB/c mice. These
results suggest that in BALB/c mice, the malate that is removed from the TCA cycle in serovar Typhimurium
SR-11 for conversion to pyruvate must be replenished by succinate or one of its precursors, e.g., arginine or
ornithine, which might be available in mouse phagocytes.
In sensitive mice, Salmonella enterica serovar Typhimurium
causes a systemic, often fatal disease, similar to human typhoid
fever (42). After ingestion, serovar Typhimurium survives
passage through the acidic environment of the stomach and
reaches the terminal ileum, where within 30 min it invades M
cells in the Peyer’s patches (21). Within 60 min, the M cells are
destroyed, and serovar Typhimurium gains access to both ad-
jacent enterocytes and underlying lymphoid cells in the mes-
enteric lymph follicles of the Peyer’s patches (21, 23). Serovar
Typhimurium then increases logarithmically in Peyer’s patches
for 2 days (20) and simultaneously disseminates systemically to
the liver and spleen, where it grows in macrophages (39, 42).
Mice usually become ruffled and lethargic 3 to 5 days after oral
infection and normally die within 7 to 12 days.
Recently, we reported that the tricarboxylic acid (TCA) cy-
cle of serovar Typhimurium strain SR-11 (hereafter called
SR-11) must operate as a complete cycle for SR-11 to be fully
virulent during BALB/c mouse infections (47). In addition to
requiring cyclic operation of the TCA cycle, it appears that
malate must be withdrawn from the TCA cycle to generate
pyruvate (Fig. 1), i.e., an SR-11 sfcA maeB mutant, unable
to make the “malic” enzymes for conversion of malate to
pyruvate (3, 25), was attenuated (47). Removing malate from
the TCA cycle to make pyruvate requires that the TCA cycle
be replenished so that intermediates will not be depleted.
Replenishment of malate does not require the glyoxylate bypass,
since an SR-11 aceA mutant, which is unable to make isoci-
trate lyase (26) and is therefore unable to make malate or
succinate from isocitrate, was fully virulent (47). Moreover,
oxaloacetate was shown not to be replenished by the conver-
sion of phosphoenolpyruvate (PEP) to oxoloacetate (Fig. 1),
i.e., an SR-11 ppc mutant, unable to make PEP carboxylase
(40), was shown to be fully virulent (47).
Although a complete TCA cycle appeared to be required for
full SR-11 virulence, deleting different TCA cycle genes re-
sulted in different levels of attenuation (47). We found that an
SR-11 sucAB mutant, unable to convert -ketoglutarate to
succinyl-coenzyme A (CoA) via the 2-oxoglutarate dehydroge-
nase complex (10, 36), was avirulent; an SR-11 sucCD mu-
tant, unable to generate succinate from succinyl-CoA via suc-
cinyl-CoA synthetase (4, 10), was moderately attenuated; an
SR-11 sdhCDA mutant, unable to generate fumarate from
succinate via succinate dehydrogenase (10, 37), was slightly
attenuated; and an SR-11 mdh mutant, unable to convert
malate to oxaloacetate via malate dehydrogenase (10, 52), was
highly attenuated. On the other hand, mutants that could not
run the reductive branch of the TCA cycle, i.e., an SR-11
aspA mutant (aspartase), unable to convert aspartate to fu-
marate (10, 45), and an SR-11 frdABCD mutant (fumarate
reductase), unable to convert fumarate to succinate (7, 10, 34),
were fully virulent (47).
It was not surprising that the SR-11 sucAB mutant was
avirulent because the strain is unable to make succinyl-CoA,
which, in addition to being converted to succinate in the TCA
cycle, is required for biosynthesis of diaminopimelate, a pre-
cursor for the synthesis of lysine, methionine, and peptidogly-
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can (5, 6, 16, 17, 29). However, it was surprising that the SR-11
sdhCDA mutant was far less attenuated than the SR-11
sucCD mutant. This discrepancy was partially explained by
our finding that an SR-11 frdABCD sdhCDA double mutant
was avirulent (30), which meant that fumarate reductase,
which normally runs in the opposite direction to succinate
dehydrogenase for branched TCA cycle operation, could substi-
tute for succinate dehydrogenase in the SR-11 sdhCDA mutant
during infection to run a full TCA cycle with only a slight
reduction in virulence. It is well known that fumarate reductase
and succinate dehydrogenase are physiologically reversible
isoenzymes that are induced under anaerobic and aerobic con-
ditions, respectively (7, 19).
While the data suggested that the conversion of succinate to
fumarate is key to SR-11 virulence (30), we wanted to know
whether it was required in Peyer’s patches or when SR-11
became systemic. We found that wild-type SR-11 and the
SR-11 frdABCD sdhCDA mutant grew at the same rate and
to the same extent in Peyer’s patches (30), suggesting that the
conversion of succinate to fumarate was required after SR-11
became systemic, i.e., presumably in phagocytes. In support of
this view, after oral infection, the SR-11 frdABCD sdhCDA
mutant did not grow well in the liver and spleen relative to
the growth of wild-type SR-11 (30). Moreover, the SR-11
frdABCD sdhCDA mutant was highly attenuated when mice
were injected with 104 CFU via the intraperitoneal route (30).
The finding that the SR-11 double mutant lacking succinate
dehydrogenase and fumarate reductase was avirulent raised a
new question. Why did blocking the conversion of succinate to
fumarate in SR-11 result in avirulence whereas blocking the
preceding step in the TCA cycle, conversion of succinyl-CoA to
succinate (Fig. 1), resulted in only moderate attenuation (47)?
Since malate appears to be used for the production of pyruvate
during infection and therefore must be replenished (47) and
since the glyoxylate bypass appeared not to be required for
virulence (47), we suggested the possibility that there might
be enough succinate, perhaps in the mitochondria of mouse
phagocytes (e.g., neutrophils, macrophages, monocytes, and
dendritic cells), to be used to replenish malate in the SR-11
TCA cycle. Alternatively, since arginine and ornithine play
major roles in the nitric oxide synthesis that is thought to limit
Salmonella growth in macrophages (8, 51) and since serovar
Typhimurium has all the genes required to transport and de-
grade either arginine or ornithine to succinate (27, 38), we
suggested that there might be enough arginine or ornithine
present in phagocytes for use by SR-11 to replenish succinate
and then malate in its TCA cycle. If so, and if there was
insufficient fumarate or malate present in mouse phagocytes to
replenish malate in the SR-11 TCA cycle, succinate conversion
to fumarate would be key to the production of pyruvate and
oxaloacetate and hence to SR-11 virulence. This scenario
would explain why blocking conversion of succinyl-CoA to
succinate results in attenuation whereas blocking conversion of
succinate to fumarate has a far more dramatic effect. If the
hypothesis that mouse phagocytes can replenish succinate, but
not fumarate or malate, in SR-11 is true, we would expect that
SR-11 mutants that are unable to convert fumarate to malate
(18) or are unable to generate either pyruvate or oxaloacetate
from malate (Fig. 1) would both be avirulent. In the present
study, we examined these possibilities.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth media. The bacterial strains and
plasmids used in this study are listed in Table 1. LB broth, Lennox (Difco
Laboratories, Detroit, Michigan); LB agar, Lennox (Difco); and MacConkey
agar (Difco) were prepared according to the package instructions. Liquid M9
minimal salts medium (32) was supplemented with either reagent grade glucose
(0.4% [wt/wt]) or sodium succinate (0.4% [wt/wt]) as the sole source of carbon
and energy. When necessary, the pH was adjusted to 7.2. SOC medium was
prepared as described by Datsenko and Wanner (12). Agar plates were supple-
mented with nalidixic acid (50 g/ml) and/or chloramphenicol (30 g/ml), as
appropriate.
Construction and characterization of SR-11 strains. All mutants were con-
structed by allelic-exchange mutagenesis using a chloramphenicol cassette as
described by Datsenko and Wanner (12). The primers used to construct the
mutants are listed in Table 2. The constructs were verified by PCR and sequenc-
ing. Primers were designed by referring to the complete genome of S. enterica
serovar Typhimurium LT2 (27). The 1,817-bp deletion in the SR-11 dcuB
fumB mutant begins in the dcuB gene 171 bp upstream of the fumB start codon
and includes an additional 1,646-bp deletion of the entire fumB open reading
frame. The primers used for confirming the size of the dcuB fumB deletion by
sequencing were as follows: forward, 5-CTG CAG GGG ATG CAG 22 TTT
AT-3; reverse, 5-GTC TTT GGC TGG ATC TTT GC-3. The 3,216-bp dele-
tion in the SR-11 fumAC mutant begins 421 bp downstream of the fumA start
codon and ends after deletion of the entire fumC open reading frame. The
primers used for confirming the size of the fumAC deletion by sequencing were
as follows: forward, 5-ATT CTT TTC GAT GGC GTC AC-3; reverse, 5-CTG
GAA CGG GAA TAT CAG GA-3. The “restored” SR-11 dcuB fumB
FIG. 1. Embden-Meyerhoff pathway, gluconeogenic pathway, and
TCA cycle. The arrows indicate the physiological directions of the
reactions. The genes encoding the enzymes for each reaction are listed
beside the reaction.
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mutant was constructed by replacing the fumAC::cat deletion in the SR-11
fumAC::cat dcuB fumB mutant with the SR-11 fumAC wild-type sequence
using the method described by Datsenko and Wanner (12). The “restored”
SR-11 sfcA maeB mutant was constructed by replacing the mdh::cat deletion
in the SR-11 sfcA maeB mdh::cat triple mutant with SR-11 mdh wild-type
sequence by the same method. The primers for these constructions are listed in
Table 2. The primers used for confirming the restoration of the wild-type genes
in these strains by sequencing are the same as those for restoring the wild-type
sequences and are listed in Table 2. The “restored” SR-11 dcuB fumB mutant
and the “restored” SR-11 sfcA maeB mutant were selected after plating
transformants on M9 minimal agar plates containing sodium succinate (0.4%
[wt/wt]) as the sole carbon and energy source. As expected, the “restored” SR-11
dcuB fumB mutant and the “restored” SR-11 sfcA maeB mutant were
chloramphenicol sensitive and, unlike their parents, grew in M9 minimal medium
containing succinate (0.4% [wt/wt]) as the sole carbon and energy source. For
sequencing, PCR products were purified with a Qiagen Qiaquick PCR purifica-
tion kit (Qiagen, MD) following the manufacturer’s instructions. PCR products
were submitted to the Rhode Island Genomics and Sequencing Center at the
University of Rhode Island. After completion of the cycle sequencing, samples
were purified with Agencourt’s CleanSEQ SPRI reagent and separated on an
Applied Biosystems 3130xl genetic analyzer (50-cm capillary array with POP7
polymer).
Growth on glucose and sodium succinate in M9 minimal medium. For testing
the growth of strains in M9 minimal medium containing glucose as the sole
TABLE 1. Strains of serovar Typhimurium and plasmids used in this study
Strain or plasmid Genotypea or relevant characteristics Defect(s) Source orreference
SR-11 wild type gyr-1816 None 11
SR-11 aceA gyr-1816 aceA::cat Isocitrate lyase 47
SR-11 sucCD gyr-1816 sucCD::cat Succinyl-CoA synthetase 47
SR-11 sucCD aceA gyr-1816 sucCD aceA::cat Succinyl-CoA synthetase, isocitrate lyase This study
SR-11 fumAC gyr-1816 fumAC::cat Fumarase A, fumarase C This study
SR-11 dcuB fumB gyr-1816 dcuB fumB::cat DcuB dicarboxylate antiporter, fumarase B This study
SR-11 fumAC dcuB fumB gyr-1816 fumAC::cat dcuB fumB DcuB dicarboxylate antiporter, fumarase
A, fumarase C, fumaraseB
This study
“Restored” SR-11 dcuB fumB gyr-1816 dcuB fumB DcuB dicarboxylate antiporter, fumarase B This study
SR-11 sfcA maeB gyr-1816 maeB sfcA::kan Both malate oxidoreductases 47
SR-11 mdh gyr-1816 mdh::cat Malate dehydrogenase 47
SR-11 sfcA maeB mdh gyr-1816 sfcA maeB mdh::cat Both malate oxidoreductases, malate
dehydrogenase
This study
“Restored” SR-11 sfcA maeB gyr-1816 sfcA maeB Both malate oxidoreductases This study
Plasmids
pKD3 Template plasmid; contains chloramphenicol
resistance cassette flanked by FLP
recombinase target sites; bla cat
12
pKD4 Template plasmid; contains kanamycin
resistance cassette flanked by FLP
recombinase target sites; bla kan
12
pKD46 Temperature-sensitive plasmid; contains
arabinose-inducible phage  red
recombinase gene for linear DNA
exchange; bla
12
pCP20 Temperature-sensitive plasmid; contains
FLP recombinase gene for removal of
antibiotic resistance cassetes; bla cat
12
a All mutants were constructed using either the chloramphenicol or kanamycin resistance cassette as described by Datsenko and Wanner (12). The resistance cassettes
were removed from the deleted genes lacking the ::cat or ::kan designation as described by Datsenko and Wanner (12).
TABLE 2. Sequences of primers used to construct serovar Typhimurium strains
Gene
Primer (5 3 3)
Forward Reverse
aceA GTA TTG AGG CGA TTT ATC TTT CAG GCT
GGC AGG TGG CGG CAG ATG GTG TAG
GCT GGA GCT GCT TCG
ATG CAT GCG CCA GGT CGA ACA TGT TGA
ACC ACA TGC TGT GGA TGC CAT ATG
AAT ATC CTC CTT AGT
mdh CGT ATC CAG CAT AGC GTC CAG CGA
ATG TTG CTC GAA AGC GCT CAG GTG
TAG GCT GGA GCT GCT TCG
CAT CGC TCC AGT GAC TCC CGG TGT GGC
CGT TGA TTT GAG CCA CAT CAT ATG
AAT ATC CTC CTT AGT
Wild-type mdh CGA TAA GAC GTG AGG AGT CAG CCG ATC CGG ATT ACG
fumB CAG GTT ATT TCG CGC AGT TAG CGC
ACT GTT TGC TGA CAA TCT GCT GGA
AGT GTA GGC TGG AGC TGC TTC G
TTC CGG CAC AAC CCG TAT TGG CCG CTT
CGT CAT TAA CCA CAG CTT CAT TCC
ATA TGA ATA TCC TCC TTA GT
fumAC TAA CCT GCG CTA TTC ACA GAA CGC
GGC GCT GGA TAT GTA CAA AGA GGT
CGT GTA GGC TGG AGC TGC TTC G
TCA TAC TGC CAA CCA TCA ACT CCG GAC
GTA CCC AGG CGT CGA ACT CCT CCA
TAT GAA TAT CCT CCT TAG T
Wild-type fumAC ATT CTT TTC GAT GGC GTC AC CTG GAA CGG GAA TAT CAG GA
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carbon and energy source, overnight cultures grown in LB broth, Lennox, were
washed twice in M9 minimal medium (no carbon source), 100 l of the washed
cultures was transferred to 10 ml of M9 minimal medium containing reagent
grade glucose (0.4% [wt/wt]) as the sole carbon and energy source, and the
cultures were incubated at 37°C with shaking overnight in 125-ml tissue culture
bottles. The same protocol used for growth on glucose was used for testing the
growth of the strains on sodium succinate (0.4% [wt/wt]) as the sole carbon and
energy source. In all growth experiments, growth was monitored spectrophoto-
metrically (A600) using a Pharmacia Biotech Ultrospec 2000 UV/Visible spec-
trophotometer.
Virulence assays. For virulence assays, the wild-type and mutant SR-11 strains
were grown overnight in LB broth, Lennox. Each strain grew to an A600 of about
3.3. Wild-type SR-11 grew with a generation time of about 33 min in LB broth,
Lennox, and each mutant grew with a generation time of about 39 min. Virulence
assays were carried out as described previously (1, 50). Briefly, 4-week-old 13- to
15-g female BALB/c mice (Charles River Laboratories, Wilmington, MA) were
housed no more than four per cage, with pine shavings as bedding. Prior to
infection, the mice were starved for food and water for 4 h. Following starvation,
50 l of 10% sodium bicarbonate was administered orally to each mouse in order
to neutralize gastric acidity, and 30 min later, 108 CFU of a specific strain in 20
l of phosphate-buffered saline (pH 7.4) containing 0.1% gelatin (BSG) was
administered orally to each of four mice. After infection, food and water were
returned, and the mice were inspected four times daily for obvious signs of illness
(ruffled fur, eyes crusted and closed, loss of appetite, or crouching and shivering)
and death. The data presented here are composites of at least two identical but
independent experiments.
Definitions of fully virulent, attenuated, and avirulent. When mice infected
with a specific mutant remained healthy, i.e., showed no signs of illness through-
out the 30-day duration of the experiment, the mutant was considered to be
avirulent. The term fully virulent was used when mice infected with a particular
mutant showed the same signs of illness as mice infected with the wild-type
SR-11 strain and the survival curve was not statistically different from that of
mice infected with the wild-type SR-11 strain. The term attenuated was used
when the mice infected with a particular mutant showed signs of illness, death
was delayed, and the survival curve was statistically different from that of mice
infected with the wild-type SR-11 strain. The extent to which death was delayed
is denoted by either the term slightly attenuated, attenuated, or highly attenu-
ated.
Protection assays. Thirty days after oral infection with an avirulent SR-11
mutant, which is sufficient time for mice to mount an intestinal mucosal immu-
nological response and a systemic immunological response, BALB/c mice were
challenged orally with 108 CFU of wild-type SR-11, as described above. In each
experiment, an age-matched set of sham-vaccinated BALB/c mice were also
challenged with 108 CFU of wild-type SR-11. The mice were then observed four
times daily for obvious signs of illness (ruffled fur, eyes crusted and closed, loss
of appetite, or crouching and shivering) and death.
Statistics. Mouse survival curves were compared for differences using the
Kaplan-Meier method (MedCalc Software, Belgium). Survival curves were con-
sidered to be different if the P value was less than 0.05.
RESULTS
An SR-11 sucCD aceA mutant is no more attenuated than
an SR-11 sucCD mutant. A major question relating to the
requirement for a complete TCA cycle for SR-11 virulence was
raised by our previous data (30, 47). Why did blocking the
conversion of succinate to fumarate (frdABCD sdhCDA) in
SR-11 result in avirulence whereas blocking the conversion of
succinyl-CoA to succinate (sucCD), which precedes succinate
conversion to fumarate in the TCA cycle (Fig. 1), resulted in
only moderate attenuation (47)? Since neither fatty acid deg-
radation nor the glyoxylate bypass was required for full SR-11
virulence (47) and a full TCA cycle appeared to be required for
SR-11 growth only after it became systemic (30), we suggested
the possibility that succinate or one of its precursors, i.e., ar-
ginine or ornithine, present in mouse phagocytes normally
replenishes TCA cycle intermediates. In this case, some malate
would be made for conversion to pyruvate and oxaloacetate in
an SR-11 sucCD mutant in vivo, resulting in attenuation,
whereas there would be no malate generated in the SR-11
frdABCD sdhCDA mutant, resulting in avirulence. How-
ever, there was the alternative possibility that the glyoxylate
bypass was induced in vivo in an SR-11 sucCD mutant,
thereby generating both succinate and malate for conversion to
pyruvate and oxaloacetate (Fig. 1). To test this possibility, we
constructed an SR-11 sucCD aceA double mutant, unable to
convert succinyl-CoA to succinate in the TCA cycle and unable
to generate succinate and malate from isocitrate via the glyoxy-
late bypass but, unlike the SR-11 frdABCD sdhCDA mutant,
still able to grow using succinate as the sole source of carbon
and energy (not shown), and tested it for virulence in BALB/c
mice (108 CFU/mouse by the oral route, about 103 times the
wild-type 50% lethal dose [LD50] [11]). As illustrated in Fig. 2,
the SR-11 sucCD aceA double mutant was attenuated (P 
0.0001) but not avirulent and was no more attenuated than the
SR-11 sucCD mutant (see Fig. 4B in reference 47). It there-
fore appears that the glyoxylate bypass plays no role in the
attenuated virulence of the SR-11 sucCD mutant, making it
more likely that replenishment of succinate in the SR-11 TCA
cycle by succinate or a precursor of succinate present in mouse
phagocytes is required for full SR-11 virulence in BALB/c
mice.
An SR-11 dcuB fumB mutant is fully virulent (108 CFU/
mouse by the oral route). If the hypothesis that the conversion
of succinate to fumarate is key to SR-11 virulence because it is
the major route to production of malate for conversion to both
pyruvate and oxaloacetate (47) is true, then an SR-11 mutant
unable to convert fumarate to malate should be avirulent.
There are three fumarases in Escherichia coli, fumarase A,
fumarase B, and fumarase C, encoded by fumA, fumB, and
fumC, respectively (2, 31, 54). Fumarase A is the major active
E. coli fumarase under microaerophilic conditions (49). E. coli
fumarase B has a higher affinity for malate than for fumarate
and appears to operate under anaerobic conditions to generate
fumarate from malate (49, 55). Fumarase C is highly active
under aerobic growth conditions (49). Homologs of fumarase
A, fumarase B, and fumarase C that are, respectively, 95%,
92%, and 91% identical to those present in E. coli MG1655 are
present in serovar Typhimurium (3, 27).
In E. coli and serovar Typhimurium, the fumB gene is im-
FIG. 2. Survival of BALB/c mice infected orally with 108 CFU of
either wild-type SR-11 (f) or the SR-11 sucCD aceA mutant (E).
1400 MERCADO-LUBO ET AL. INFECT. IMMUN.
 o
n
 O
ctober 31, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
mediately downstream of the dcuB gene (3, 27). The dcuB gene
(for dicarboxylate uptake) encodes a C4 dicarboxylate anti-
porter for malate influx and succinate efflux (44). The fumB
and dcuB genes are induced under anaerobic conditions when
fumarate acts as a terminal electron acceptor (2, 44, 49). In the
example cited above, succinate would be exchanged for malate,
which would then be converted to fumarate by fumarase B, and
fumarate would be converted to succinate by fumarate reduc-
tase. This scenario seems unlikely to be of value to SR-11 in
vivo in view of the fact that fumarate reductase is not required
for full SR-11 virulence (47). However, since DcuB also trans-
ports fumarate anaerobically (44), it was also possible that
DcuB and fumarase B play roles in vivo in the conversion of
fumarate to malate, in which case an SR-11 dcuB fumB
mutant would be attenuated. To determine whether the dcuB
and fumB genes play roles in SR-11 virulence, BALB/c mice
were infected orally with 108 CFU (i.e., about 103 times the
wild-type LD50 [11]) of either wild-type SR-11 or an SR-11
dcuB fumB mutant. The SR-11 dcuB fumB mutant ap-
peared to be fully virulent (Fig. 3A), although statistically it
was slightly less virulent than its parent (P  0.03). These
results suggest that neither C4 dicarboxylate transport by DcuB
nor fumarase B plays a major role in the conversion of fuma-
rate to malate by SR-11 during infection of BALB/c mice.
An SR-11 fumAC mutant is attenuated and an SR-11
fumAC dcuB fumB mutant is avirulent (108 CFU/mouse
by the oral route). Since it appears that fumarase B plays no
major role in SR-11 virulence in BALB/c mice (Fig. 3A), we
tested the virulence of an SR-11 fumAC mutant, unable to
make both fumarase A and fumarase C. BALB/c mice were
infected orally with 108 CFU (i.e., about 103 times the wild-
type LD50 [11]) of either wild-type SR-11 or SR-11 fumAC.
The SR-11 fumAC mutant was attenuated (P  0.0004) but
not avirulent (Fig. 3B). In fact, mice infected with the SR-11
fumAC double mutant that survived the 30-day duration of
the experiment still appeared sick (ruffled fur, crusted eyes,
and lethargic). These results suggest that either fumarase A or
fumarase C or both play a role in SR-11 virulence.
It was possible that the SR-11 fumAC mutant was not
avirulent because endogenous fumarase B could substitute
somewhat for fumarase A and/or fumarase C. BALB/c mice
were therefore infected orally with 108 CFU (i.e., about 103
times the wild-type LD50 [11]) of either wild-type SR-11 or an
SR-11 fumAC dcuB fumB mutant. The SR-11 fumAC
FIG. 3. Survival of BALB/c mice infected orally with 108 CFU of either wild-type SR-11 (f) or the SR-11 dcuB fumB mutant (E) (A), 108
CFU of either wild-type SR-11 (f) or the SR-11 fumAC mutant (E) (B),108 CFU of either wild-type SR-11 (f) or the SR-11 fumAC dcuB
fumB mutant (E) (C), or 108 CFU of either wild-type SR-11 (f) or the SR-11 “restored” dcuB fumB mutant (E) (D).
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dcuB fumB mutant was indeed avirulent (P  0.0001), i.e.,
mice infected with wild-type SR-11 all died within 10 days
postinfection (Fig. 3C), whereas the mice infected with the
SR-11 fumAC dcuB fumB mutant remained completely
healthy throughout the 30-day duration of the experiment (Fig.
3C). Since SR-11 became avirulent only when all three fuma-
rase genes were deleted, it appears that if both fumarase A and
fumarase C are not available in vivo, fumarase B can substitute
and convert fumarate to malate, albeit not at the rate required
for full virulence (Fig. 3B).
The SR-11 fumAC dcuB fumB mutant was constructed
by inserting the fumAC deletion into the SR-11 dcuB
fumB mutant. To prove conclusively that the deletions were
responsible for the avirulence of the SR-11 fumAC dcuB
fumB mutant, the wild-type fumAC genes were reinserted
into the mutant to regenerate the SR-11 dcuB fumB mutant
(see Materials and Methods). Although the SR-11 fumAC
dcuB fumB mutant grows well with glucose as the sole
source of carbon and energy (not shown), it fails to grow using
succinate as the sole carbon and energy source (not shown)
because it cannot carry out the conversion of fumarate to
malate and therefore is unable to perform gluconeogenesis;
however, the “restored” SR-11 dcuB fumB mutant grew
with succinate as the sole source of carbon and energy (not
shown) and, like the original SR-11 dcuB fumB mutant, was
fully virulent (P  0.44) (Fig. 3D). Therefore, collectively, the
data strongly suggest that preventing fumarate from being con-
verted to malate by the three fumarases in SR-11 renders
SR-11 completely avirulent in BALB/c mice.
An SR-11 sfcA maeB mdh triple mutant is avirulent
(108 CFU/mouse by the oral route). Previously, we showed that
an SR-11 sfcA maeB mutant, unable to convert malate to
pyruvate, and an SR-11 mdh mutant, unable to convert
malate to oxaloacetate, were both attenuated in BALB/c mice
but not completely avirulent (47). If the conversion of succi-
nate to fumarate is key to SR-11 virulence because the fuma-
rate then provides the major source of malate for conversion to
both pyruvate and oxaloacetate during infection of BALB/c
mice, an SR-11 sfcA maeB mdh mutant should be aviru-
lent. To address this question, BALB/c mice were infected
orally with 108 CFU of either wild-type SR-11 or an SR-11
sfcA maeB mdh mutant. Mice infected with wild-type
SR-11 all died within 10 days postinfection (Fig. 4A), whereas
the mice infected with the SR-11 sfcA maeB mdh mutant
remained completely healthy throughout the 30-day duration
of the experiment (Fig. 4A), i.e., the triple mutant was com-
pletely avirulent (P  0.0001).
The SR-11 sfcA maeB mdh mutant was constructed by
inserting the mdh deletion into the SR-11 sfcA maeB mu-
tant. To prove conclusively that the inability of the SR-11
sfcA maeB mdh mutant to convert malate to pyruvate and
oxaloacetate was responsible for its avirulence, the wild-type
mdh gene was reinserted into the SR-11 sfcA maeB mdh
mutant to regenerate the SR-11 sfcA maeB mutant (see
Materials and Methods). While the SR-11 sfcA maeB mdh
mutant grows well with glucose as the sole source of carbon
and energy (not shown), it fails to grow using succinate as the
sole carbon and energy source because it is unable to convert
malate to either pyruvate or oxaloacetate and is therefore
unable to carry out gluconeogenesis. The SR-11 sfcA maeB
mutant grows with succinate as the sole source of carbon and
energy, since it is able to convert oxaloacetate to PEP and is
therefore able to carry out gluconeogenesis (Fig. 1). As ex-
pected, the “restored” SR-11 sfcA maeB mutant grew with
succinate as the sole source of carbon and energy (not shown)
and, like the original SR-11 sfcA maeB mutant, was atten-
uated (P  0.015) but not avirulent (Fig. 4B). Collectively,
these data suggest that preventing malate from being con-
verted to either pyruvate or oxaloacetate attenuates SR-11
virulence but preventing malate from being converted to both
pyruvate and oxaloacetate renders it completely avirulent in
BALB/c mice.
The SR-11 fumAC dcuB fumB mutant and the sfcA
maeB mdh mutant are immunogenic. To this point, the data
suggested that the SR-11 frdABCD sdhCDA mutant, the
SR-11 fumAC dcuB fumB mutant, and the SR-11 sfcA
maeB mdh mutant are avirulent for the same reason, i.e.,
because they are all unable to make malate for conversion to
both pyruvate and oxaloacetate. In addition to being avirulent,
we found previously that the SR-11 frdABCD sdhCDA mu-
tant was immunogenic, i.e., mice orally vaccinated with the
SR-11 frdABCD sdhCDA mutant were completely pro-
tected when challenged 30 days later with the virulent wild-
type SR-11 (30). It therefore seemed likely that if the three
FIG. 4. Survival of BALB/c mice infected orally with 108 CFU of
either wild-type SR-11 (f) or the SR-11 sfcA maeB mdh mutant
(E) (A) or 108 CFU of either wild-type SR-11 (f) or the “restored”
SR-11 sfcA maeB mutant (E) (B).
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mutants are avirulent for the same reason, they should all be
immunogenic. To this end, BALB/c mice originally fed either
108 CFU of the SR-11 fumAC dcuB fumB mutant or the
sfcA maeB mdh mutant were orally challenged with 108
CFU of the wild-type SR-11 30 days later. The mice never
appeared ill and remained healthy both throughout the initial
30 days of the experiment and during the ensuing 30 days after
challenge with wild-type SR-11, whereas sham-infected mice
orally challenged with 108 CFU of the wild-type SR-11 30 days
after sham infection all died within 12 days (Fig. 5). Therefore,
like mice infected with the SR-11 frdABCD sdhCDA mu-
tant, mice infected with either the SR-11 fumAC dcuB
fumB mutant or the sfcA maeB mdh mutant were fully
protected against challenge with wild-type SR-11 (P 0.0001).
DISCUSSION
In a recent study, we showed that fatty acid degradation, the
glyoxylate bypass, gluconeogenesis, and the anaplerotic replen-
ishment of oxaloacetate in the TCA cycle from PEP did not
appear to be needed for full SR-11 virulence in BALB/c mice,
but cyclic operation of the TCA cycle and the formation of
both pyruvate and oxaloacetate from malate were required
(47). Removal of malate from the TCA cycle to produce pyru-
vate requires that TCA cycle intermediates be replenished to
keep the TCA cycle operative. However, since it appeared that
the glyoxylate bypass was not needed for full virulence (47),
replenishment of TCA cycle intermediates did not seem to
occur by this pathway. Thus, the data were consistent with the
hypothesis that during infection of BALB/c mice, SR-11 grows
in a mixed mode using limiting glycolytic sugars and either
amino acids or intermediates of the TCA cycle to replenish it,
thereby allowing continuous formation of pyruvate from
malate.
In a subsequent report, we showed that although an SR-11
frdABCD mutant, unable to make fumarate reductase, was
fully virulent in BALB/c mice and an SR-11 sdhCDA mutant,
unable to make succinate dehydrogenase, was only slightly
attenuated, an SR-11 frdABCD sdhCDA mutant was aviru-
lent (30). These data strengthened the hypothesis that a com-
plete TCA cycle is necessary for SR-11 virulence and suggested
that fumarate reductase, which normally runs in the opposite
direction to succinate dehydrogenase for branched TCA cycle
operation, can substitute for succinate dehydrogenase in the
SR-11 sdhCDA mutant during infection to run a full TCA
cycle with only a slight reduction in virulence. In addition, since
an SR-11 sucCD mutant that could not convert succinyl-CoA
to succinate was only moderately attenuated (47), the data
suggested that the conversion of succinate to fumarate is key to
SR-11 virulence.
In this study, we have presented data showing that in addi-
tion to an SR-11 frdABCD sdhCDA mutant being avirulent,
both an SR-11 fumAC dcuB fumB mutant and an SR-11
sfcA maeB mdh mutant are also avirulent. The common
feature shared by these mutants is that they are all unable to
generate malate for the production of both pyruvate and oxa-
loacetate (47). However, blocking the conversion of succinyl-
CoA to succinate, which precedes the conversion of succinate
to fumarate in the TCA cycle (Fig. 1), should also result in the
inability to generate malate, yet an SR-11 sucCD mutant is
only moderately attenuated (47), and as shown here, an SR-11
sucCD aceA mutant is no more attenuated than an SR-11
sucCD mutant (Fig. 2), ruling out the possibility that the
glyoxylate bypass becomes important in the SR-11 sucCD
mutant to generate malate. Moreover, unlike SR-11 frd-
ABCD sdhCDA, SR-11 fumAC dcuB fumB, and SR-11
sfcA maeB mdh, the SR-11 sucCD aceA mutant grows
with succinate as the sole source of carbon and energy.
Collectively, these data can be explained as follows. We
suggest that succinate, ornithine, or arginine present in mouse
phagocytes replenishes succinate in the SR-11 TCA cycle. Suc-
cinate is then converted to fumarate, then to malate, and then
to pyruvate and oxaloacetate. Since malate and subsequently
pyruvate and oxaloacetate could be synthesized from replen-
ished succinate in the SR-11 sucCD mutant but could not be
made by theSR-11 frdABCD sdhCDA, SR-11 fumAC
dcuB fumB, or SR-11 sfcA maeB mdh mutant (Fig. 1),
the SR-11 sucCD mutant could retain some virulence. More
work will be necessary to test this hypothesis; however, it will
be of great interest if arginine present in mouse phagocytes is
found to be used by SR-11 to replenish succinate in its TCA
cycle, since arginine is used for nitric oxide synthesis (8) and
nitric oxide is thought to limit the growth of Salmonella in
macrophages (51). Consequently, if this scenario is correct,
arginine utilization by SR-11 in macrophages would not only
support SR-11 virulence by replenishing TCA cycle interme-
diates, but might limit nitric oxide synthesis and thereby fur-
ther promote SR-11 virulence.
Why is the formation of pyruvate from malate necessary for
full SR-11 virulence? The ability of SR-11 to generate PEP
from pyruvate has a minimal effect on virulence, i.e., we pre-
viously showed that an SR-11 ppsA pckA double mutant,
unable to make PEP either from oxaloacetate via PEP car-
boxykinase, encoded by the pckA gene (28), or from pyruvate
via PEP synthase, encoded by the ppsA gene (35), was at most
slightly attenuated (47). It therefore appears that the require-
ment for malate to be converted to pyruvate for full virulence
FIG. 5. Survival of BALB/c mice initially sham infected orally and
infected 30 days later with 108 CFU of wild-type SR-11 (f), initially
infected orally with 108 CFU of the SR-11 fumAC dcuB fumB
mutant and infected 30 days later with 108 CFU of wild-type SR-11
(E), or initially infected orally with 108 CFU of the SR-11 sfcA
maeB mdh mutant and infected 30 days later with 108 CFU of
wild-type SR-11 (‚).
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is not for the generation of PEP and suggests that insufficient
pyruvate is produced by glycolytic reactions to fulfill the pre-
cursor metabolite requirements for biosynthesis of one or
more of the following classes of compounds: (i) alanine, valine,
isoleucine, and leucine for protein synthesis; (ii) acetyl-CoA
for the synthesis of fatty acids and membrane phospholipids;
(iii) acetyl-CoA to keep the TCA cycle operative; and (iv)
acetyl-CoA for the synthesis of acetyl-phosphate, a known reg-
ulator of virulence genes (22). In any case, the fact that not
enough pyruvate is generated through glycolysis for full viru-
lence suggests that SR-11 grows in an environment scarce in
glycolytic sugars in vivo.
Upon entry into a host phagocyte, serovar Typhimurium
resides and replicates within a membrane-bound compartment
called a Salmonella-containing vacuole (SCV) (14, 39). Recent
evidence suggests that replication of serovar Typhimurium in
the SCV of a single phagocyte in either the liver or spleen is
limited during acute infection, usually not exceeding two or
three doublings (41, 43). Furthermore, it appears that serovar
Typhimurium increases in numbers in the liver by spreading
from one phagocyte to others nearby, thereby forming a focus
of infection (43). However, it appears that during acute infec-
tion some serovar Typhimurium cells leave one focus of infec-
tion to form other foci of infection (43). Thus, although serovar
Typhimurium grows poorly in infected phagocytes, it grows to
high numbers in the liver because it spreads to form numerous
foci of infection (43). Although several nonnutritional host
factors have been implicated in limiting serovar Typhimurium
growth in the SCV (15, 48), our data suggest that the poor
growth may, at least in part, be due to a scarcity of carbon
sources.
While gluconeogenesis and isocitrate lyase of the glyoxylate
bypass appear not to be necessary for acute serovar Typhi-
murium infection in BALB/c mice (13, 47), isocitrate lyase
does appear to be required for chronic serovar Typhimurium
infection (13). Moreover, several other bacterial and fungal
pathogens appear to require either gluconeogenesis or isoci-
trate lyase, or both, for virulence (9, 24, 33, 46, 53, 56). It
therefore appears that different intracellular pathogens have
evolved different strategies for success within phagocytes. In
fact, recent evidence suggests the possibility that serovar Ty-
phimurium, and perhaps other intracellular pathogens, orches-
trates host responses to reduce the growth rate within phago-
cytes for successful infection (15). One of the orchestrations
that intracellular pathogens choose may be to alter the phago-
some or the phagolysosome membrane to limit the transport of
various carbon sources. If so, since, as described above, differ-
ent intracellular pathogens appear to have chosen different
strategies for growth, it may be that different pathogens limit
the transport of different carbon sources during infection.
On a practical note, it is clear that the SR-11 frdABCD
sdhCDA, SR-11 fumAC dcuB fumB, and SR-11 sfcA
maeB mdh mutants are not only avirulent, they effectively
protect BALB/c mice against subsequent infection with wild-
type SR-11. In this context, it would be of great interest to
determine whether these mutants are avirulent in humans and
animals and can also protect them against infection by their
virulent parents and whether, if the mutants are able to meet
the energy requirements for foreign-antigen production, they
might be effective as vehicles for genes that express virulence
antigens of unrelated pathogens to induce protective immunity
against those pathogens.
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